Thornhill Medical
Brad Ashley is currently serving as Venture Advisor at Storytime Capital and Chairman and Director at Thornhill Medical. Brad is also a Director at ACG Toronto Chapter and the Managing Partner at PRIVEQ Capital Funds, a Private Equity fund based in Toronto, Canada. With a diverse background in finance and investment management, Brad has held various advisory and management roles in companies such as AlayaCare, HUB, CVCA, VenGrowth Capital Funds, Ernst & Young Orenda Corporate Finance, and JP Morgan Canada. Brad has an impressive educational background, holding degrees from Institute of Corporate Directors, York University - Osgoode Hall Law School, Schulich School of Business - York University, and University of Waterloo.
This person is not in the org chart
This person is not in any teams
Thornhill Medical
Briefly, what does your company do?*Thornhill, an innovative SME is the inventor, developer and supplier of novel and valuable healthcare systems and devices important in emergency, mobile, and remote/austere health delivery sectors. This includes EMS, Humanitarian, Public Safety and Military and other “challenging circumstance” applications.Thornhill is internationally recognized as a leader in the precise control and management of arterial blood gases. This expertise has allowed it to develop and supply a range of novel, IP protected, portable, medical systems that are able to provide critical life support functions to those deployed in challenging circumstances. Thornhill Medical delivers unique and valuable solutions that include 1) MOVES® SLC™: a portable life support for casualty care during patient transport, in field hospitals and forward surgical suites; 2) ClearMateTM: immediate and effective treatment for carbon monoxide poisoning; 3) MADMTM: mobile anesthesia; and 4) RespirAct™ RA-MR: an investigational tool used in diagnostic procedures which measure vascular reactivity.Thornhill differentiates itself in this market via its superior understanding of the utilization of arterial blood gases, thus eliminating, or substantially reducing the bulk, weight, cost and logistic burdens of other products, while optimizing patient outcomes. The efficacy of its solutions is recognized globally, with the United States Marine Corps, the Government of Ontario and the Federal Government of Canada being notable customers.